AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19

Published by
Reuters

(Reuters) -AstraZeneca’s experimental COVID-19 antibody drug cocktail succeeded in reducing severe disease or death in non-hospitalised patients in a late-stage study, the British drugmaker said on Monday. The drug, called AZD7442, reduced the risk of developing severe COVID-19 or death by 50% in patients who had been symptomatic for seven days or less, meeting the main goal of the trial. “An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, executive vice president, b…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *